New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity
Open Access
- 1 May 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 11592-11609
Abstract
Compstatin-class macrocyclic peptides have emerged as therapeutic complement modulators, with a PEGylated compstatin derivative being approved and sequence-optimized analogs with enhanced PK/PD properties showing clinical promise. By extending structure-activity relationship studies of compstatin, we identified a modification (V3I) that enhances the target affinity up to 30-fold. Analog Cp01-V3I represents the most potent proteinogenic compstatin (KD = 20 nM), opening paths toward recombinant applications. Introducing the V3I modification into late-generation compstatin analogs yielded a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, featuring potent complement inhibition in vitro. Cryogenic electron microscopy of the C3bB-Cp60 complex at 2.88 Å resolution confirmed the structural basis for enhanced target affinity and provided mechanistic insights. Lastly, we demonstrate that Cp60s ultralong target residence time enables diagnostic applications for detecting complement opsonins on biosurfaces. Collectively, this work highlights the importance of rigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.Keywords
All Related Versions
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (205321_204607205321_204607)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_219969310030_219969)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_17610431003A_176104)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (TMPFP3_224990TMPFP3_224990)
- Universität Basel
This publication has 64 references indexed in Scilit:
- Assay System Based on Metabolic Glycoengineering‐Enabled Click Chemistry for the Efficient Evaluation of Complement‐Regulatory Peptide Coatings on Endothelial CellsAdvanced Materials Interfaces, 2025
- Complement‐targeted therapeutics: Are we there yet, or just getting started?European Journal of Immunology, 2024
- Complement‐targeted therapeutics: An emerging field enabled by academic drug discoveryAmerican Journal of Hematology, 2023
- UCSF ChimeraX: Structure visualization for researchers, educators, and developersProtein Science, 2020
- The Clinical Trials Portfolio for On-label and Off-label Studies of EculizumabJAMA Internal Medicine, 2020
- Current developments in Coot for macromolecular model building of Electron Cryo‐microscopy and Crystallographic DataProtein Science, 2019
- Evaluation of Complement Function by ELISA2013
- Species specificity of the complement inhibitor compstatin investigated by all‐atom molecular dynamics simulationsProteins: Structure, Function, and Bioinformatics, 2010
- Reference distributions for complement proteins C3 and C4: A practical, simple and clinically relevant approach in a large cohortJournal of Clinical Laboratory Analysis, 2004
- Solution structure of Compstatin, a potent complement inhibitorProtein Science, 1998